This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
Good to see that a CLL drug is recognized by the larger pharmaceutical world for the break through that it is.
Brian Koffman 10/30/15
NORTH CHICAGO, Ill., Oct. 28, 2015 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that IMBRUVICA® (ibrutinib) was awarded the prestigious Prix Galien 2015 Award for Best Pharmaceutical Agent. IMBRUVICA won this distinction out of 24 category nominees, all of which were deemed innovative in the field of medicine and were approved by the U.S. Food and Drug Administration (FDA) within the past five years. IMBRUVICA is jointly developed and commercialized by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.
“We are honored that IMBRUVICA, a first-in-class, oral therapy has been recognized by the Prix Galien USA Committee for the role it continues to play in treating patients with certain blood cancers,” said Erik von Borcke, President of Pharmacyclics. “Our goal is to continue developing clinically meaningful, scientifically sound therapies that offer healthcare professionals and their patients the opportunity at the best possible outcome, allowing them to resume as normal a life as possible.”
Considered to be the biomedical industry’s highest accolade, the Prix Galien Award recognizes outstanding achievement in the development of new therapies. The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien Award is generally regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.
To see the full news release: http://news.sys-con.com/node/3525863